MTOR and triple-negative breast carcinoma: We chose four everolimus resistant triple-negative breast cancer cell lines, MDA-MB-231, MDA-MB-436, BT20 and HCC1143, characterized by a diversity of activated signaling pathways and proliferation inhibition by ATP competitive inhibitors to mTOR.